Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Hoffmann-La Roche
Baylor College of Medicine
Karyopharm Therapeutics Inc
Haihe Biopharma Co., Ltd.
Duke University
Fred Hutchinson Cancer Center
Adela, Inc
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Istituto Oncologico Veneto IRCCS
Turning Point Therapeutics, Inc.
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Young Adult Survivors United
AVM Biotechnology Inc
Centre Leon Berard
Hospices Civils de Lyon
Washington University School of Medicine
Essen Biotech
Institut Bergonié
Children's Oncology Group
Region Skane
National Cancer Centre, Singapore
University Health Network, Toronto
IGM Biosciences, Inc.
Lantern Pharma Inc.
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
Ipsen
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cyteir Therapeutics, Inc.